H1N1sw Vaccine in Adult Transplant Recipients
A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers
Sponsor: HepNet Study House, German Liverfoundation
Terminated
End of H1N1 Swine Flu Pandemic
Other Immunocompromised trials with similar outcome
Listed as NCT01069601, this PHASE2 trial focuses on Immunocompromised and remains terminated or withdrawn. Sponsored by HepNet Study House, German Liverfoundation, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- HepNet Study House, German Liverfoundation
For direct contact, visit the study record on ClinicalTrials.gov .